Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
- 主要终点
- Overall survival
研究概览
简要总结
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
详细描述
This study is a multi-center, retrospective and observational real-world study to explore the efficacy, safety and treatment pattern of TACE combined with Atezolizumab + Bevacizumab in unresectable hepatocellular carcinoma. The target population for the planned retrospective analysis of this project is patients who have been diagnosed with unresectable HCC according to the guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) and treated with TACE combined with atezolizumab + bevacizumab.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients were diagnosed with unresectable hepatocellular carcinoma according to the guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition);
- •Patients ≥ 18 years old, male or female;
- •Child-Pugh Class A and B liver function;
- •ECOG-PS score of 0 ~ 2 points;
- •Received TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
排除标准
- •Other primary malignancies;
- •Incomplete data, such as no baseline image that can be assessed according to RECIST 1.1 or mRECIST, and survival outcome.
结局指标
主要结局
Overall survival
时间窗: 1 year
Overall survival (OS): defined as the time from the start of the first TACE or atezolizumab + bevacizumab (whichever occurs first) to death due to any cause.
次要结局
- Objective response rate(1 year)
- Immune-TACE PFS(1 year)
- Progression-Free Survival(1 year)
- Disease control rate(1 year)
- Treatment pattern(1 year)
- One-year survival rate(1 year)
研究者
Gao-jun Teng
Dr. Gao-Jun Teng
Zhongda Hospital